EU set to back Novavax Covid vaccine
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
THURSDAY, MAY 19, 2022
THURSDAY, MAY 19, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
EU set to back Novavax Covid vaccine

Coronavirus chronicle

BSS/AFP
20 December, 2021, 10:00 am
Last modified: 20 December, 2021, 10:03 am

Related News

  • EU rushes out $300 billion roadmap to ditch Russian energy
  • EU needs a few more days for next sanctions package on Russia - Germany
  • EU braces for storm as Ukraine fallout cascades in economy
  • EU wants Bangladesh to quickly amend EPZ Labour Act
  • China voices discontent with EU-Japan position on Senkaku islands

EU set to back Novavax Covid vaccine

Novavax says its vaccine showed 90.4 percent efficacy against Covid-19 in a North American trial

BSS/AFP
20 December, 2021, 10:00 am
Last modified: 20 December, 2021, 10:03 am
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

The EU's drug regulator will decide Monday whether to approve a Covid jab by Novavax, which uses a more conventional technology that the US biotech firm hopes will reduce vaccine hesitancy.

Novavax's jab, a protein-based vaccine of the kind used around the world to protect against many childhood illnesses, would be the fifth coronavirus shot authorised for the European Union.

Approval would also be a boost for the Maryland company, whose jab has been plagued by delays.

The European Medicines Agency (EMA) said its human medicines committee would hold an extraordinary meeting to decide on Novavax on Monday, and "will communicate the outcome".

The EU has already signed a deal to buy up to 200 million doses of the two-shot vaccine pending approval by the Amsterdam-based watchdog.

Novavax says its vaccine showed 90.4 percent efficacy against Covid-19 in a North American trial.

Chief executive Stanley Erck said the firm "looks forward to providing an additional vaccine option in Europe, built on a proven, well-understood technology platform".

The vaccine "may help address major obstacles to global vaccination, including global distribution challenges and vaccine hesitancy", Erck added.

All vaccines work by teaching the body's immune system to attack the coronavirus, but they do it in different ways.

Novavax's so-called protein subunit technology is already tried and tested, having been used for decades to vaccinate people against diseases including hepatitis B and whooping cough.

It also means it does not have to be stored in ultra-low temperatures, potentially giving it a logistical edge over some other jabs.

- 'Production problems' -

Novavax uses tiny, lab-made fragments of a protein found on the surface of the coronavirus spike.

When injected, these trigger a reaction by the immune system, so that if it later comes into contact with the Covid virus, it knows to attack it.

By contrast, the Pfizer-BioNTech and Moderna vaccines have dominated the global Covid response using pioneering, but hitherto largely untested Messenger RNA (mRNA) technology.

They use a molecule of genetic material known as RNA to deliver a message to cells to produce the spike protein themselves. The body's immune system then learns to recognise the protein and attack it.

The viral vector approach used by AstraZeneca and Johnson & Johnson works on a similar principle, but delivers the genetic message via a version of the common cold adenovirus as a "vector".

Rare but serious side effects of heart inflammation have been reported with the mRNA vaccines, and blood clots with the viral vector vaccines.

But Novavax has struggled with months of delays amid what a group of MEPs recently called "production problems".

Indonesia and the Philippines have already approved the Novavax jab, while Japan has agreed to buy 150 million doses.

Novavax says it has also filed for approval in Britain, India, Australia, New Zealand, Canada, and with the World Health Organization.

The company has also said it is "evaluating its vaccine against the Omicron variant" and working on an Omicron-specific version.

    
 
 

Top News / World+Biz / Europe

EU / Novavax

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Ice cream business thrives on Eid sales, warm weather
    Ice cream business thrives on Eid sales, warm weather
  • Picture: Collected
    Abdul Gaffar Choudhury passes away
  • Milk: Pricier at retail level, yet farmers deprived of fair price
    Milk: Pricier at retail level, yet farmers deprived of fair price

MOST VIEWED

  • Medical staff members check the temperature of people as they enter at Capital Airport, following an outbreak of Covid-19, in Beijing, China, 5 November, 2020. Photo: Reuters
    China relaxes some Covid test rules for US, other travellers
  • Representational image.
    China Junshi's potential Covid drug shows promise in small trial
  • A woman wearing protective mask walks at a sidewalk near business district in Jakarta, Indonesia March 2, 2020. REUTERS/Willy Kurniawan/Files
    Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • North Korean leader Kim Jong Un presides over a politburo meeting of the ruling Workers' Party, amid the coronavirus disease (COVID-19) pandemic, May 17, 2022, in this photo released May 18, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • North Korea Covid outbreak is 'worrying' for new variants -WHO
    North Korea Covid outbreak is 'worrying' for new variants -WHO
  • People watch a TV broadcasting a news report on the coronavirus disease (Covid-19) outbreak in North Korea, at a railway station in Seoul, South Korea on 17 May 2022. Photo: Reuters.
    N Korea Covid outbreak could have 'devastating' impact on human rights, UN says

Related News

  • EU rushes out $300 billion roadmap to ditch Russian energy
  • EU needs a few more days for next sanctions package on Russia - Germany
  • EU braces for storm as Ukraine fallout cascades in economy
  • EU wants Bangladesh to quickly amend EPZ Labour Act
  • China voices discontent with EU-Japan position on Senkaku islands

Features

Sketch: TBS

'Food inflation is an unavoidable consequence of currency devaluation'

4h | Interviews
The open-browser-tabs question also tells an interviewer how much of an internet native the job applicant might be. Photo: Noor-a-Alam

The best question to ask a job applicant

4h | Pursuit
Illustration: TBS

Ugly business: Politics in workplace

3h | Pursuit
Illustration: TBS

‘Do you have insurance?’: Life of a life insurance agent

6h | Panorama

More Videos from TBS

Cannes Film Festival 2022 resumes after 2 years

Cannes Film Festival 2022 resumes after 2 years

18h | Videos
Pension is coming for all

Pension is coming for all

18h | Videos
Bakery business in crisis for increased raw material prices

Bakery business in crisis for increased raw material prices

20h | Videos
Foods that have the most protein

Foods that have the most protein

20h | Videos

Most Read

1
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

2
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
How Bangladesh can achieve edible oil self-sufficiency with local alternatives
Bazaar

How Bangladesh can achieve edible oil self-sufficiency with local alternatives

5
Govt tightens belt to relieve reserve
Economy

Govt tightens belt to relieve reserve

6
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab